po scorad - La Fondation pour la Dermatite Atopique

Fondation pour la Dermatite Atopique
Recherche et Education
Une fondation pour les professionnels de santé
Une fondation pour les patients atteints de dermatite atopique
Les missions
La Fondation pour la Dermatite Atopique est une
fondation d’entreprise Pierre Fabre exclusivement
dédiée à l’eczéma atopique
Une fondation pour la recherche
Les projets de recherche fondamentale ou clinique
peuvent faire l’objet d’un soutien financier après
validation par le Conseil Scientifique de la Fondation.
Une fondation pour l’éducation thérapeutique
Comme toutes les maladies chroniques, la dermatite
atopique est difficile à prendre en charge. Le découragement
gagne souvent enfants et parents qui ne comprennent pas
toujours comment tirer le meilleur parti des traitements
disponibles. L’éducation thérapeutique met en œuvre des
moyens adaptés pour apporter les connaissances nécessaires,
un savoir-faire et un savoir-être précieux.
La Fondation pour la Dermatite Atopique aide le
développement des centres d’éducation thérapeutique.
Les membres fondateurs
Pierre Fabre Dermocosmétique
Laboratoires A-Derma
Laboratoires Dermatologiques Avène
Pierre Fabre Dermatologie
Laboratoires Dermatologiques Ducray
Laboratoires Klorane
Pierre Fabre Médicament
Le Conseil d’Administration
Collège de Professeurs
Professeur Yves De Prost
(Paris)
Professeur François Bernard Michel
(Montpellier)
Professeur Jean Revuz
(Paris)
Conseil Scientifique
Professeur Carle Paul
(Hôpital Larrey - Toulouse)
Professeur Jean-François Nicolas
(Centre Hospitalier - Lyon Sud)
Professeur Jean-François Stalder
(Hôtel Dieu - Nantes)
Aider la recherche
dans le domaine de la dermatite atopique
Etude sur les récepteurs
à l’histamine
PO SCORAD
Experimental dermatology • Original article
Allergy
ORIGINAL ARTICLE
SKIN AND EYE DISEASES
Patient-Oriented SCORAD (PO-SCORAD): a new selfassessment scale in atopic dermatitis validated in Europe
Association between copy-number variations of the human
histamine H4 receptor gene and atopic dermatitis in a Chinese
population
J.-F. Stalder1, S. Barbarot1, A. Wollenberg2, E. A. Holm3, L. De Raeve4, S. Seidenari5, A. Oranje6,
M. Deleuran7, F. Cambazard8, A. Svensson9, D. Simon10, E. Benfeldt11, T. Reunala12,
J. Mazereeuv13, F. Boralevi14, B. Kunz15, L. Misery16, C. G. Mortz17, U. Darsow18, C. Gelmetti19,
T. Diepgen20, J. Ring18,21, M. Moehrenschlager21, U. Gieler22 & A. Taı̈eb14, for the PO-SCORAD
Investigators Group*
B. Chen,1 T. Ye,1,2,3 Y. Shao,1,2,3 J. Zhang,1,2,3 Q. Zhong,1,2,3 X. Hu,1,2,3 W. Zhang4 and B. Yu1,2,3
Dermatology Department and Shenzhen Key Discipline of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China; Shenzhen Key
Laboratory for Translational Medicine of Dermatology and Biomedical Research Institute, Shenzhen PKU-HKUST Medical Center, Shenzhen, China
Department of Dermatology, Nantes University Hospital, Nantes, France; Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany; Skin Clinic in Ballerup, ‘‘Helsehuset’’, Ballerup, Denmark; Department of Dermatology UZ Brussels, Vrije Universiteit
Brussel, Brussel, Belgium; Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy; University Hospital
Rotterdam and Erasmus University, Rotterdam, the Netherlands; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark;
Jean Monet Faculty, Saint-Etienne, France; Department of Dermatology, Skane University Hospital, Malmö, Sweden; Department of
Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Dermato-allergology, Copenhagen
University Hospital Gentofte, Hellerup, Denmark; Medical School, Tampere University, Tampere, Finland; Department of Dermatology and
André Hospital,
Paul Sabatier University, Larrey Hospital, Toulouse, France; Department of Dermatology and Pediatric Dermatology, St Andre
Bordeaux, France; Dermatologikum Hamburg, Hamburg, Germany; Department of Dermatology, Brest University Hospital, Brest, France;
Department of Dermatology and Allergy centre, Odense University Hospital, Odense, Denmark; Deptartment of Dermatology and Allergy
nchen and Division of Environmental Dermatology and Allergy, Helmholtz Center/Tum, Munich, GerBiederstein, Technische Universität München
many; Department of Anesthesia, Intensive care and Dermatologic Sciences, Fondazione Ca’ Granda ‘‘Ospedale Maggiore Policlinico’’, Milan,
Italy; University Hospital Heidelberg, Department of Social Medicine, Center of Occupational & Environmental Dermatology, Heidelberg,
Germany; Hochgebirgsklinik Davos-Wolfgang, Christine-Kuehne Centre for Allergy Research and Education (CK-CARE), Davos, Switzerland;
Department of Psychosomatic Medicine-Psychodermatology, University of Giessen, Giessen, Germany
doi:10.1111/ced.12117
Summary
To cite this article:: Stalder J-F, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D,
Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taıeb
Taı̈
Taı̈eb A,
for the PO-SCORAD Investigators Group. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy
2011; 66: 1114–1121.
Keywords
atopic dermatitis (MesH); eczema score;
patient-oriented; SCORing of Atopic
Dermatitis index; self-assessment score.
Correspondence
Pr. Jean-François Stalder, Service de
Dermatologie, CHU de Nantes, Hôtel Dieu,
44035 Nantes, France.
Tel.: +33-2-40-08-31-15
Fax: +33-2-40-08-31-17
E-mail: [email protected]
*The PO-SCORAD investigator group is
listed in the Acknowledgments section
Accepted for publication 12 February 2011
DOI:10.1111/j.1398-9995.2011.02577.x
Edited by: Hans-Uwe Simon
Abstract
Background: Patient-oriented medicine is an emerging concept, encouraged by the World
Health Organization, to greater involvement of the patient in the management of chronic
diseases. The Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) index is a
self-assessment score allowing the patient to comprehensively evaluate the actual course
of atopic dermatitis (AD), using subjective and objective criteria derived mainly from the
SCORAD, a validated AD severity clinical assessment tool.
Objectives: To validate the PO-SCORAD index in a large European population of
patients exhibiting all forms of AD severity by assessing its correlation with the
SCORAD index.
Patients/methods: Four hundred and seventy-one patients (185 adults, 286 children) consulting for AD in hospitals from 9 European countries were recruited. The investigators
and the patients used the SCORAD and PO-SCORAD scales, respectively, to assess AD
severity at inclusion (D0) and 28 ± 7 days later (D28).
Results: Patient-Oriented SCORing Atopic Dermatitis and SCORAD scores were significantly correlated at D0 [r = 0.67 (95% CI: 0.62; 0.72), P < 0.0001]. Consistency was confirmed at D28, with a stronger linear correlation between both scales [r = 0.79 (95% CI:
0.75; 0.83), P < 0.0001]. Absolute changes from baseline in SCORAD and PO-SCORAD
scores were also significantly correlated [r= 0.71 (95% CI: 0.64; 0.76), P < 0.0001].
Although no specific intervention was investigated, AD improved over the study, with a
decrease of PO-SCORAD and SCORAD scores from D0 to D28 by )19.19% and )24.39%,
respectively. The consistency of the correlations was similar in the adult and children groups.
Conclusions: This study validated the use of PO-SCORAD to self-assess AD severity
and demonstrated its good correlation with SCORAD.
Background. Atopic dermatitis (AD) is a chronic, relapsing allergic skin disease.
The histamine H4 receptor (HRH4) has been shown to be associated with a number
of autoimmune disorders, including AD.
Aim. To explore a possible association between copy-number variations (CNVs) of
the HRH4 gene and the risk of AD in a Chinese population.
Methods. Genomic DNA and RNA were collected from 541 patients with AD and
613 healthy controls, and the CNVs and mRNA levels of HRH4 were examined.
ELISA was used to measure the levels of IgE in all participants.
Results. Amplifications of HRH4 copy numbers were associated with the risk of
developing AD (P < 0.05, OR = 1.85, 95% CI 1.30–2.63), whereas deletions of HRH4
copy numbers were not associated with disease risk for AD (P = 0.30, OR = 0.82,
95% CI 0.57–1.19). HRH4 mRNA levels were much higher in samples with HRH4
copy-number amplifications than in those without such amplifications (P < 0.05). IgE
levels were associated with amplifications (P < 0.05, OR = 1.96, 95% CI 1.19–3.25),
but not with deletions (P = 0.63, OR = 0.87, 95% CI 0.49–1.54) of HRH4 copy
numbers.
Conclusions. CNVs of the HRH4 gene are associated with AD in a Chinese
population.
Introduction
Atopic dermatitis (AD) is a chronic relapsing allergic
skin disease characterized by typically distributed
eczematous skin lesions and intense pruritus. AD affects
15–20% of children and 2–10%
2
of adults.1,2 The
Correspondence: Dr Bo Yu, Dermatology Department, Peking University
Shenzhen Hospital, no. 1120, Lianhua Road, Futian District, Shenzhen
Guangdong 518036, China
E-mail: [email protected]
Conflict of interest: none declared.
The first two authors have contributed equally to this study, and should
be considered joint first authors.
Accepted for publication 4 November 2012
aetiology of AD remains unclear, but it is recognized to
be a complex genetic disorder. Family and twin studies
also support a significant genetic predisposition to AD.3
Up to now, genetic studies have indicated that AD is
associated with the Nod-like receptor (NLR) family
genes, such as C3 and CD14.4–6
Histamine plays an important role in allergic and
autoimmune diseases. Four histamine receptor subtypes, HRH1–4, have been identified. Of these, HRH1
and HRH2 are recognized as the main histamine receptor subtypes affecting inflammation and other immune
responses, and have been used for treatment of AD and
other immune and inflammatory diseases.7,8 HRH4 is
the most recently described histamine receptor, which
was independently cloned and characterized by several
ª The Author(s)
CED ª 2013 British Association of Dermatologists Clinical and Experimental Dermatology, 38, 295–301
Allergy 66 (2011) 1114–1121 ª 2011 John Wiley & Sons A/S
1114
CED
Clinical and Experimental Dermatology
CPD
295
NS
ATORY INVESTIGATIO
CLINICAL AND LABOR
Pediatric Dermatology
International
Guidelines
Etude sur la
corticophobie
1–6, 2013
tion in Atopic
Therapeutic Patient Educa
Experiences
Dermatitis: Worldwide
M.D.,†
Linda De Raeve, M.D.,
M.D.,* Alan Ball, B.A.,*
M.D.,* Claire Bernier,
Marcoux, M.D.,¶
Jean-Francois Stalder,
Deleuran, M.D.,§ Danielle
Uwe Gieler, M.D.,‡ Mette
Sue Lewis-Jones, M.D.,‡‡
, M.D.,** Peter Lio, M.D.,††
Lawrence F. Eichenfield
Christine Chiaverini, M.D.,***
ucation
Roberto Takaoka, M.D.,¶¶
Carlo Gelmetti, M.D.,§§
and for the Oriented Patient-Ed
M.D.,*
Barbarot,
bastien
Sébastien
(OPENED)
Laurent Misery, M.D.,†††
Network in Dermatology
UZ
Department of Dermatology
Nantes, France, †Department
ic Medicine, Nantes University Hospital, ‡Department
Department of Psychosomat
*Department of Dermatology
, Aarhus University
Brussel, Brussels, Belgium,
Department of Dermatology
§Department
Brussels, Vrije Universiteit
of Giessen, Giessen, Germany, Justine University Hospital, Montreal, Canada,
, St.
,
Psychodermatology, University
Department of Dermatology
¶Department
Departmentt of Dermatology
††Departmen
San Diego, California,
Hospital, Aarhus, Denmark,
Medical
, Rady Children’s Hospital,
, Ninewells Hospital and
Departmentt of Dermatology
**Departmen
Departmentt of Dermatology
Fondazione
Chicago, Illinois, ‡‡Departmen
and Dermatological Sciences,
Care
Intensive
Children’s Memorial Hospital,
, University of Sao Paulo
Departmentt of Anesthesia,
§§Departmen
Departmentt of Dermatology
¶¶Departmen
ent
School, Dundee, Scotland,
Department
†††Departm
Policlinico, Milan, Italy,
Hospital, Nice, France,
Ca’ Granda Ospedale Maggiore ***Departm
ent of Dermatology, Archet
Department
Brazil,
Hospital, Brest, France
Medical School, Sao Paulo,
of Dermatology, University
has proven effective
in
patient education (TPE)
of life (QoL) for
Abstract: Therapeutic
and improving quality
adherence
atopic dermatitis
increasing treatment
chronic diseases, especially TPE experiences
patients with numerous
worldwide
undertaken to identify
(AD). This study was
located in 11 countries,
from 23 hospitals,
in TPE programs
in AD treatment. Experts
e on 10 major items. Patients
AD or
responded to a questionnair
moderate to severe
and adolescents with
were used.
were mainly children
and collective approaches
Individual
QoL.
varied from one to six
markedly affected
the number of sessions
were
Depending on the center,
and 20 to 200 patients
12 hours of education),
(corresponding to 2 to
team comprised multidisciEach center’s education
followed each year.
psychologists). Evaluations
nurses,
doctors,
(e.g.,
s
some
plinary professional
satisfaction index, or
assessment, QoL, a
from
were based on clinical
was obtained, it came
three. When funding
companies (Germany),
combination of the
(France), insurance
role
regional health authorities pharmaceutical firms (Japan, Italy). The
or
in
donations (United States),
but their involvement
was always highlighted,
Despite
of patient associations
country to another.
varied from one
the increasing
the TPE process
our findings demonstrate
the nonexhaustive approach,
BJD
British Journal of Dermatology
C L I N I C A L A N D L A B O R A T O R Y I N V E S TI G A T I O N S
Topical corticosteroid phobia in atopic dermatitis: a study
of its nature, origins and frequency
H. Aubert-Wastiaux, L. Moret,* A. Le Rhun,* A.M. Fontenoy,* J.M. Nguyen,* C. Leux,* L. Misery,� P. Young,�
M. Chastaing,� N. Danou,§ P. Lombrail,* F. Boralevi,– J.P. Lacour,** J. Mazereeuw-Hautier,�� J.-F. Stalder and
S. Barbarot
The FASEB Journal article fj.10-168658. Published online January 31, 2011.
Department of Dermatology, CHU Hôtel-Dieu, 1 place Alexis Ricordeau, 44035 Nantes Cedex 1, France
*PIMESP (Pôle d’Information Médicale et de Santé Publique), CHU Hôtel-Dieu, Nantes, France
�Department of Dermatology, CHU Morvan, Brest, France
�Dermatologist, Rouen, France
§Dermatologist, Paris, France
–Pediatric Dermatology Unit, Hôpital Pellegrin-Enfants, CHU Bordeaux, Bordeaux, France
**Department of Dermatology, CHU Archet, Nice, France
��Department of Dermatology, CHU Larrey, Toulouse, France
The FASEB Journal • Research Communication
Hélène
Hele
Hé
lèlene Aubert-Wastiaux.
E-mail: [email protected]
Accepted for publication
28 May 2011
Funding sources
This study was sponsored by the Foundation for
Atopic Dermatitis, Pierre Fabre Laboratoire
(Toulouse, France), which provided funds to cover
logistic expenses (e.g. printing the questionnaires),
but had no access to the data collected and played
no role in their analysis, the writing of the
manuscript or the decision to submit it for
publication.
Conflicts of interest
None declared.
DOI 10.1111/j.1365-2133.2011.10449.x
Background Topical corticosteroids remain the mainstay of atopic dermatitis therapy. Many atopic dermatitis therapeutic failures appear to be attributable to poor
adherence to treatment due to topical corticosteroid phobia.
Objectives To assess the facets, origins and frequency of fear of topical corticosteroid use among patients with atopic dermatitis.
Methods A questionnaire comprising 69 items, generated from information gathered during interviews with 21 patients and 15 health professionals, was given
to consecutive patients consulting at the outpatient dermatology departments of
five regional university hospitals or with 53 dermatologists in private practice.
Results A total of 208 questionnaires were analysed (including 144 from parents
80Æ7% of the
and 87 from adult patients, 27 of whom were also parents); 80
respondents reported having fears about topical corticosteroids and 36% admitted
nonadherence to treatment. A correlation was found between topical corticosteroid phobia and the need for reassurance, the belief that topical corticosteroids
pass through the skin into the bloodstream, a prior adverse event, inconsistent
information about the quantity of cream to apply, a desire to self-treat for the
shortest time possible or poor treatment adherence. Topical corticosteroid phobia
was not correlated with atopic dermatitis severity.
Conclusion Topical corticosteroid phobia is a genuine and complex phenomenon,
common among French patients with atopic dermatitis, that has an important
impact on treatment compliance.
As defined by the U.K. Working Party’s diagnostic criteria,1 atopic dermatitis (AD) is a relapsing, chronic, inflammatory, cutaneous disorder that occurs mainly in childhood and sometimes
persists into adulthood. AD currently affects 10–20% of children
worldwide.2,3 It is a public health concern because of its prevalence, cost and impact on quality of life.4,5 Thus, the broad
impact of AD warrants optimization of relevant support services.
Topical corticosteroids (TCS), the mainstay of AD treatment,
are often required for months or years to control the disease.
Although they have long been known to have side-effects,
their efficacy and safety, when used appropriately, are well
established.6–10 Why some patients with AD do not respond
to TCS remains unexplained, but poor adherence to the prescribed regimen may underlie treatment failure. Indeed,
adherence by patients with AD is known to be poor, at
~30%,11 as it is for other chronic diseases.12
What is usually called corticosteroid phobia is frequent.
Corticosteroid phobia is certainly a misnomer because the
term ‘phobia’ defines an irrational fear.13 In fact, corticosteroid phobia is the dedicated term to describe all types of fear
about steroid use. In routine clinical practice, it is not unusual
for patients to express fear or anxiety about using TCS and
TCS phobia appears to be common (60–73% of patients),14,15
potentially leading to poor adherence and lack of response to
� 2011 The Authors
808
DOI: 10.1111/pde.12024
1
Julie Henry,* Chiung-Yueh Hsu,* Marek Haftek,† Rachida Nachat,*
Heleen D. de Koning,‡ Isabelle Gardinal-Galera,*,§ Kiyotaka Hitomi,� Stéfana Balica,§
Catherine Jean-Decoster,¶ Anne-Marie Schmitt,¶ Carle Paul,*,§ Guy Serre,*
and Michel Simon*,1
Summary
Correspondence
M.D., Service
to Jean Francois Stalder,
Address correspondence
44035 Nantes,
de Nantes–Hôtel Dieu,
de Dermatologie, CHU
com.
France, or e-mail: jfstalder@mac.
Hornerin is a component of the epidermal cornified
cell envelopes
BJD � 2011 British Association of Dermatologists 2011 165, pp808–814
Inc.
© 2013 Wiley Periodicals,
*Centre National de la Recherche Scientifique (CNRS)-Toulouse III University UMR5165, Institut
Fédératif de Recherche 150 (INSERM-CNRS-Université Paul Sabatier-Centre Hospitalier
Universitaire), Toulouse, France; †Lyon I University EA4169, Lyon, France; ‡Department of
Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;
§
Department of Dermatology, Toulouse University Hospital, Toulouse, France; �Graduate School of
Bioagricultural Sciences, Nagoya University, Naboya, Japan; and ¶Centre Européen de Recherche sur
la Peau et les Epithéliums de Revêtement, Pierre Fabre Dermo-Cosmétique, Toulouse, France
A single-nucleotide polymorphism within
the gene encoding hornerin (HRNR) has recently been
linked with atopic dermatitis (AD) susceptibility. HRNR
shares features with filaggrin, a key protein for keratinocyte differentiation, but conflicting reports have been
published concerning its expression in the epidermis, and
its role is still unknown. To analyze HRNR expression and
function in the epidermis, anti-HRNR antibodies were
produced and used in Western blot analysis and immunohistochemical, confocal, and immunoelectron microscopy
analyses of human skin and of cornified cell envelopes
purified from plantar stratum corneum. We also tested
whether HRNR was a substrate of transglutaminases. In
the epidermis, HRNR was detected at the periphery of
keratohyalin granules in the upper granular layer and at
the corneocyte periphery in the whole cornified layer.
Detected in Western blot analysis as numerous bands,
HRNR was relatively insoluble and only extracted from
epidermis with urea and/or reducing agents. The presence of HRNR in the purified envelopes was confirmed
by immunoelectron microscopy and by Western blot
analysis after V8-protease digestion. HRNR was shown to
be a substrate of transglutaminase 3. These data demonstrate that HRNR is a component of cornified cell envelopes of human epidermis. Its reduced expression in AD
may contribute to the epidermal barrier defect observed
in the disease.—Henry, J., Hsu, C.-Y., Haftek, M., Nachat,
R., de Koning, H. D., Gardinal-Galera, I., Hitomi, K.,
Balica, S., Jean-Decoster, C., Schmitt, A.-M., Paul, C.,
Serre, G., Simon, M. Hornerin is a component of the
epidermal cornified cell envelopes. FASEB J. 25, 000– 000
(2011). www.fasebj.org
ABSTRACT
Etude sur
la filaggrine
Key Words: atopic dermatitis � skin � keratinocytes � transglutaminase � terminal differentiation � corneocytes
Differentiation of the epidermis is an oriented
process during which keratinocytes of the basal layer
undergo a series of metabolic and structural changes
0892-6638/11/0025-0001 © FASEB
throughout their migration to the surface of the skin.
Cornification, the later stages of the process, is a real
programmed cell death, and results in the formation of
corneocytes. It is the stacking up of these anucleate
cells, forming the outermost layer or stratum corneum
(also called cornified layer), that enables the epidermis
to fulfill one of its main functions: it provides a multiple
barrier between the body and its environment by
opposing water loss and the penetration of exogenous
molecules, UV radiation, and pathogens, and by protecting the body, because of its great mechanical resistance. Alterations in keratinocyte differentiation are
involved in the pathophysiology of many skin diseases,
e.g.,, atopic dermatitis (AD; OMIM%603635).
AD is a common chronic inflammatory skin disease
affecting 15–20% of children and 1–3% of adults in
industrialized countries. It is often linked with other
atopic conditions, such as asthma and allergic rhinitis.
AD results from complex interactions between genetic
and environmental factors. The pathogenesis of the
disease is still poorly understood, although immune
system dysfunctions, as well as defects in the epidermal
barrier, have long been suspected (1– 4). A major
breakthrough was the discovery (5) that loss-of-function
mutations in the gene encoding filaggrin (FLG) on
chromosome 1q21 are a major risk factor for AD, with
an estimated odds ratio �3 (for a review, see ref. 6).
This strengthens the hypothesis of a stratum corneum
failure as a primary event, potentially leading to increased penetration of allergens and skin inflammation
(1, 2, 7). Indeed, FLG is an essential component of the
stratum corneum.
Correspondence: CNRS-UPS UMR5165, CHU Purpan, Pl.
du Dr Baylac TSA40031, 31059 Toulouse cedex 9, France.
E-mail: [email protected]
doi: 10.1096/fj.10-168658
This article includes supplemental data. Please visit http://
www.fasebj.org to obtain this information.
1
Développer
l’éducation thérapeutique
dans la dermatite atopique
Collaboration avec
plus de 35 centres dans le monde
Les outils
d’éducation thérapeutique
Vous ou votre enfant avez un
eczéma atopique
pique c’est...
L’eczéma ato
N
L’ecz
c
fair
q ue e ?
ScoRaD
po-
t...
’es
ém
a atopique
Poussée
Poussée
Une évolution
é
par poussées
po
atopique c
’
L’ecz
ma
D
-ScoRaD
Accalmie
qu
e faire ?
Accalmie
s
Le
conseils
...
e st
Des dossiers
de formation
res
s et inflammatoi
Des plaques rouge
Une peau sèche
Un chevalet
pédagogique sur la
dermatite atopique
Le jeu de l’oie
d e
La Fondation pour la Dermatite Atopique remercie le Professeur Carlo Gelmetti
pour sa collaboration dans la conception et la réalisation de ce document.
l ’ a t o p i e
Poster et BD :
«Comment appliquer
ta crème en images»
11
12
2
11
6
12
5
2
8
6
12
Les cartes
PO SCORAD
l ’ h o r l o g e
7
6
12
4
8
2
10
5
11
6
12
5
2
3
8
4
7
6
5
3
6
12
5
1
2
3
9
8
4
7
de l’atopie
1
10
9
5
1
4
7
4
7
6
12
2
11
3
8
3
4
7
11
9
1
9
2
10
3
10
5
1
8
5
1
2
11
11
6
12
9
4
7
11
10
9
3
4
7
10
3
9
2
8
L’horlo ge
1
10
1
9
4
7
12
10
3
8
8
FONDATION POUR LA DERMATITE ATOPIQUE :
RECHERCHE ET EDUCATION
Siège social : Hôtel-Dieu Saint Jacques - 2, rue Viguerie - 31000 TOULOUSE
Tel. : 33 (5) 63 58 88 95
11
1
10
9
11
6
12
5
1
10
2
Pour les parents
et le corps enseignant
Mon enfant a de l’eczéma ?
Informations données aux parents
et utiles aux enseignants
Docteur Jacques ROBERT
Pédiatre - Allergologue
3
9
8
4
7
6
5
De nombreux livres
éducatifs
Votre enfant est atteint d'eczéma
Conseils simples et réponses aux questions
les plus fréquentes des parents
Réalisée par la FONDATION POUR LA DERMATITE ATOPIQUE
u2400_Broch_FONDATION_DERM ATOP_8p.indd 1
Le PO-SCORAD
Application médicale
téléchargeable gratuitement
en 18 langues
8/09/09 11:06:41
Dr Magali Bourrel Bouttaz
Dermatologue . Chambery
ION
FON DAT
e…
r, institutric
instituteu
Vous êtes
iquer la malesadie?
Comment expl
s camarad
à Hugo et à se
du
aboration
Avec la coll
ues ROBERT
Docteur Jacq rgologue
Pédiatre
- Alle
Site internet
L’éducation thérapeutique
Pour les professionnels de santé
Le PO SCORAD
1re ÉTAPE
� L’extension de l’eczéma
Grisez les zones correspondant à votre eczéma
sur le dessin qui vous est fourni.
2e ÉTAPE
� Les différents signes à évaluer
� SURFACE DE LA PEAU
Regardez la peau où il n’y a pas d’eczéma
La peau est-elle sèche ?
� Pas du tout
� Un peu sèche
� Modérément sèche
� Extrêmement
sèche
� ERYTHÈME
Existe-t-il des zones rouges sur les plaques d’eczéma ?
� Pas du tout
� Un peu rouge
� Modérément rouge
� Extrêmement
rouge
Versions disponibles :
Version papier
Les experts vous informent
Les journées de formation ETP DAY
organisées en Italie, France et Belgique
Site internet
S’informer
Evaluer son eczéma
Vous ou votre enfant avez un
eczéma atopique
que faire ?
N
la peau
ation, reconstruire
Diminuer l’inflamm
L’ecz
atopique
c
ScoRaD
po-
q ue
inflammation
t...
’es
a
ém
Pour les patients
D
D
L’ecz
atopique c
’
po
-ScoRaD
it
L’émollient reconstru
la barrière cutanée
q ue
faire ?
s
Le
conseils
...
e st
é
de cortisone
La crème à base
réduit l’inflammation
ma
peau sèche
faire ?
Apprendre de façon ludique
FONDATION POUR LA DERMATITE ATOPIQUE - RECHERCHE ET ÉDUCATION
Hôtel-Dieu Saint Jacques - 2, rue Viguerie - 31025 TOULOUSE - Tél : 33 (5) 63 58 98 10
www.fondation-dermatite-atopique.org
Contactez-nous :
[email protected]